Core One Labs (DB:LD6) - Stock Price, News & Analysis

LD6 Stock Overview

Operates as a psychedelic research and development company. More details

LD6 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Latest financial reports are more than a year old

Does not have a meaningful market cap (€7M)

Core One Labs Inc. Competitors

Biofrontera

XTRA:B8FK

€15.8m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€57.9m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of all time highs, changes and price drops for Core One Labs
Historical stock prices
Current Share Price	CA$0.07
52 Week High	CA$0.33
52 Week Low	CA$0.025
Beta	0
11 Month Change	0%
3 Month Change	-7.85%
1 Year Change	-62.95%
33 Year Change	-92.58%
5 Year Change	-98.66%
Change since IPO	-98.53%

Recent updates

Shareholder Returns

	LD6	DE Pharmaceuticals	DE Market
7D	0%	1.4%	0.8%
1Y	-62.9%	-18.4%	9.1%

Return vs Industry: LD6 underperformed the German Pharmaceuticals industry which returned -12.7% over the past year.

Return vs Market: LD6 underperformed the German Market which returned 13.2% over the past year.

Price Volatility

Is LD6's price volatile compared to industry and market?
LD6 volatility
LD6 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: LD6's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine LD6's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	n/a	Joe Shacker	core1labs.com

Core One Labs Inc. operates as a psychedelic research and development company. The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. It also provides natural health products; news dissemination services; financing services; and operates medical clinics, as well as engages in micro cultivation.

Core One Labs Inc. Fundamentals Summary

How do Core One Labs's earnings and revenue compare to its market cap?
LD6 fundamental statistics
Market cap	€4.52m
Earnings (TTM)	-€10.57m
Revenue (TTM)	€303.19k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is LD6 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LD6 income statement (TTM)
Revenue	CA$458.54k
Cost of Revenue	CA$0
Gross Profit	CA$458.54k
Other Expenses	CA$16.44m
Earnings	-CA$15.98m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did LD6 perform over the long term?

See historical performance and comparison

LD6 Stock Overview

Risk Analysis

Core One Labs Inc. Competitors

XTRA:B8FK

€15.8m

DUSE:SBX

€27.9m

XTRA:HIGH

€57.9m

DB:0RX

€65.0m

Price History & Performance

Recent News & Updates

New major risk - Financial data availability

Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding

New minor risk - Financial data availability

Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio- Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

New major risk - Market cap size

New major risk - Shareholder dilution

Recent updates

New major risk - Financial data availability

Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding

New minor risk - Financial data availability

Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio- Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

New major risk - Market cap size

New major risk - Shareholder dilution

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease

Full year 2023 earnings released: CA$0.49 loss per share (vs CA$1.40 loss in FY 2022)

Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

Core One Labs Inc. Announces Management Changes

Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million.

Core One Labs Inc., Annual General Meeting, Feb 08, 2023

Core One Labs Inc. Prepares for Commercial Production of API-Grade Psilocybin

Less than half of directors are independent

Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction

Core One Labs Inc. Announces Resignation of Ryan Hoggan from its Board of Directors

Less than half of directors are independent

Core One Labs Inc. (CNSX:COOL) acquired Awakened Biosciences Inc.

Core One Labs Inc. Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

Core One Labs Applauds Health Canada’s Amendments to Special Access Program, Allowing Physicians to Request Patient Access to Psychedelic Treatments

Core One Labs Inc. (CNSX:COOL) acquired New Path Laboratories Inc. for CAD 3.4 million.

Core One Labs Inc. (CNSX:COOL) acquired Frontier Mycology Corp. for CAD 7.5 million.

Executive Chairman recently sold €55k worth of stock

Chief Science Officer & Director John Sanderson has left the company

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Akome Biotech Ltd.

Core One Labs Inc. (CNSX:COOL) acquired Bluejay Mental Health Group Inc.

Core One Labs in Collaboration with KICT to Explore DMT Assisted Psychotherapy

Core One Labs Inc. and Vocan Biotechnologies Inc. Initiates First Strain Production for Biosynthetic Psilocybin

Executive Chairman recently sold €65k worth of stock

Core One Labs Inc. (CNSX:COOL) entered into a letter of intent to acquire Ketamine Infusion Centers of Texas, LLC for $0.2 million.

High Tower Capital, Inc. completed the acquisition of Certain Assets of Core One Labs Inc. (CNSX : COOL).

Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to Its Patented Thinstrip Delivery Method

Core One Labs Inc. Announces Board Changes

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Vocan Biotechnologies Inc.

Shareholder Returns

Price Volatility

About the Company

Core One Labs Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue